Drug Combo Proves Powerful Against Lung Cancer Patchogue NY

A two-drug combination treatment in Patchogue proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial. In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone.

Local Companies

Kenneth D Gold
(631) 666-6752
24 E Main St
Bay Shore, NY
BONNIE KINER-STRACHAN, MD
(631) 638-1000
3 Edmund Pellegrino Road
Stony Brook, NY
Mohammad Imran Moid, MD
Health Science Ctr T-17,
Stony Brook, NY
Allen George Meek, MD
631-444-7770
University Hospital H South C 2-626,
Stony Brook, NY
Lisa Cupit, MD
631-444-2059
T-15 Rm 040,
Stony Brook, NY
Diane M Clausen
(631) 751-8305
2500 Nesconset Hwy
Stony Brook, NY
GERRY RUBIN, MD
(631) 666-0262
180 E Main Street
Bay Shore, NY
Steven A Montana, DO
631-751-8305
2500 Nesconset Hwy Bldg 26 Ste 90
Stony Brook, NY
Kenneth Warren Zamkoff, MD
336-716-9011
Uh Level 5,
Stony Brook, NY
Sumeet Chandra, MD
631-444-7788
Nicolls Rd,
Stony Brook, NY
Data Provided by:
    

Provided By:

SATURDAY, May 30 (HealthDay News) -- A two-drug combination treatment proved successful in safely slowing advanced non-small cell lung cancer in a recent clinical trial.

In the study, a phase 3 trial involving 768 people with the disease, those who had erlotinib (Tarceva) added to their dose of the bevacizumab (Avastin) saw the progression of the disease slow more than if on bevacizumab alone. People on the combo therapy tolerated the drugs well and survived an average of 4.8 months before the disease grew worse, compared with 3.7 months for those on bevacizumab alone.

Non-small cell lung cancer, often linked to past tobacco use, is the most common of all lung cancers, according to the National Cancer Institute.

"This is the first study to show the addition of erlotinib to maintenance therapy prolongs progression-free survival in patients with advanced non-small cell lung cancer," the study's co-author, Dr. Vincent Miller, a thoracic oncologist at Memorial Sloan-Kettering Cancer Center in New York City, said in a news release from the center. "Knowing which patients will get the greatest benefit from this combination, based on the identification of biomarkers, will be an important next step in this research."

Maintenance therapy aims to slow a disease from getting worse and better the chance of surviving while recovering from stronger chemotherapy treatments, which can weaken and sicken the person.

Miller was to present the findings Saturday at the annual meeting American Society of Clinical Oncology, in Orlando, Fla.

Bevacizumab and erlotinib have previously shown promise in treating non-small cell lung cancer by blocking tumor growth.

More information

The American Cancer Society has more about non-small cell lung cancer.

SOURCE: Memorial Sloan-Kettering Cancer Center, news release, May 30, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Exercise for Prostate Cancer Patchogue NY
Regular exercise may help protect men from prostate cancer, says a new study. U.S. researchers looked at 190 men who had a prostate biopsy and found that those who were moderately active -- anything equivalent to walking at a moderate pace for several hours a week -- were significantly less likely to be diagnosed with prostate cancer.
- Hormone Therapy for Lung Cancer Patchogue NY
- Exercise for Breast Cancer Survival Patchogue NY
- Genetic Clues for Skin Cancer Therapies Patchogue NY
- Side Effect Of Chemotherapy Drugs Patchogue NY
- Risks for Childhood Cancer Survivors Patchogue NY
- Hormone Therapy for Breast Cancer Patchogue NY
- Fungal Infection Treatments Patchogue NY
- Delayed Prostate Cancer Therapy Patchogue NY